Threats To Global Technology Leadership: The Biotech Paradigm

Plagued by a love-hate relationship with Wall Street and the threat of caps on drug prices, biotech companies continue to scramble for the funding needed to bring products to market. The upshot: Many have abandoned plans to become fully integrated pharmaceutical companies and are pairing with larger partners or rethinking pricing and product strategies.

October 1 1993 by Chief Executive